The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
ApexOnco Front Page
Recent articles
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
The move comes after a death in the Alpha-3 cema-cel study.
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
Jazz’s Chimerix buy faces its big test.
The first data are dribbled out, but cross-trial comparisons look uninspiring.
More data from onvansertib's phase 2 study fail to convince.
